Form D · Pharmaceuticals
Solstice Biologics LLC
San Francisco, CA · CIK 0001564178
Offering snapshot reported Dec 30, 2015 · SEC filing
- Reported sold
- $4M Offering amount: $4M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 15, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 30, 2015 | Initial | $4,000,000 | No comparison | 2 | SEC filing |
| Oct 3, 2014 | Initial | $7,500,000 | No comparison | 2 | SEC filing |
| Dec 28, 2012 | Initial | $7,500,000 | No comparison | 2 | SEC filing |
| Dec 12, 2012 | Initial | $3,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-254171
Series A-4 Preferred Stock.
Source: Form D, filed Dec 30, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Adelman | Director |
| John Borgeson | Executive |
| Curt Bradshaw | Director, Executive, Promoter |
| Steven Dowdy | Director |
| Corey Goodman | Director, Executive, Promoter |
| Frank Muhlenbeck | Director |
| George Rehm | Director |
| Louis Tartaglia | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1700 Owens Street Suite 595
San Francisco, CA, 94158
San Francisco, CA, 94158